At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 82 enrolled
Drug / intervention
Live Yellow Fever Vaccine (YFV-17D) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of the Systemic and Cutaneous Immune Responses to Yellow Fever Vaccination in Atopic Dermatitis Subjects
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jul 28, 2008·Updated Jan 13, 2014
In Brief
A Phase 2 clinical trial evaluating Live Yellow Fever Vaccine (YFV-17D) and YFV-17D Placebo for Atopic Dermatitis. Completed, enrolled 82 participants across 3 sites.
Detailed Summary
The main objective of the Atopic Dermatitis and Vaccinia Immunization Network (ADVN) is to reduce the risk of the fatal reaction, eczema vaccinatum (EV), to the smallpox vaccination in those with atopic dermatitis (AD). Since vaccination with live vaccinia virus (VV) in individuals with AD increases the risk of EV, a yellow fever vaccine was chosen. The purpose of this study is to determine the immune response to a yellow fever vaccine in adults with AD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartAug 2008
Primary CompletionApr 2011
TodayJul 2026
First PostedJul 28, 2008
Enrollment StartAug 1, 2008
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 17.9 years ago
Interventions
Live Yellow Fever Vaccine (YFV-17D)biological
YFV-17D Placebodrug